Ardent Health (NYSE:ARDT) Releases Quarterly Earnings Results, Beats Estimates By $0.22 EPS

Key Points

• Ardent Health reported quarterly earnings of $0.52 EPS, surpassing the consensus estimate by $0.01.
• Following the earnings announcement, Ardent Health's stock increased by 3.6%, reaching $10.68 per share.
• Analysts have mixed ratings for ARDT, with stock ratings that include ten "buy" ratings and an average price target of $20.30.

Ardent Health (NYSE:ARDT - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.30 by $0.22, Zacks reports. Ardent Health had a net margin of 3.73% and a return on equity of 16.07%. The firm had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.54 billion. Ardent Health updated its FY 2025 guidance to 1.730-2.01 EPS.

Ardent Health Price Performance

NYSE:ARDT opened at $10.68 on Wednesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.12 and a quick ratio of 1.98. The firm has a market cap of $1.53 billion and a price-to-earnings ratio of 6.55. The company has a 50 day moving average price of $12.87 and a 200-day moving average price of $13.53. Ardent Health has a 1-year low of $10.10 and a 1-year high of $20.72.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Mizuho reduced their price target on shares of Ardent Health from $19.00 to $18.00 and set an "outperform" rating for the company in a research report on Wednesday, April 9th. Stephens reissued an "overweight" rating and set a $21.00 price target on shares of Ardent Health in a research report on Tuesday, May 20th. Royal Bank Of Canada reissued an "outperform" rating and set a $21.00 price target on shares of Ardent Health in a research report on Thursday, May 15th. Bank of America lowered shares of Ardent Health from a "neutral" rating to an "underperform" rating and reduced their price target for the stock from $15.50 to $14.60 in a research report on Wednesday, July 16th. Finally, Guggenheim raised their price target on shares of Ardent Health from $16.00 to $18.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $20.30.

Institutional Investors Weigh In On Ardent Health

Institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. grew its stake in Ardent Health by 1,684.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 767,862 shares of the company's stock valued at $10,558,000 after acquiring an additional 724,841 shares during the period. Jane Street Group LLC grew its stake in Ardent Health by 235.1% in the 1st quarter. Jane Street Group LLC now owns 57,468 shares of the company's stock valued at $790,000 after acquiring an additional 40,318 shares during the period. Acadian Asset Management LLC grew its stake in Ardent Health by 574.9% in the 1st quarter. Acadian Asset Management LLC now owns 40,238 shares of the company's stock valued at $550,000 after acquiring an additional 34,276 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Ardent Health by 103.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,104 shares of the company's stock valued at $194,000 after acquiring an additional 7,182 shares during the period.

About Ardent Health

Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.